Sigma-Aldrich, Oxford BioMedica sue Open Biosystems

By Elaine Rigoli

Tampa, Fla., June 13 - Sigma-Aldrich and Oxford BioMedica said they have filed a lawsuit against Open Biosystems, Inc. for infringement of patents that cover key lentiviral-based systems for delivery of foreign DNA to a broad array of mammalian cells.

The complaint, which was filed in U.S. District Court Eastern District of Missouri, alleges that Open Biosystems is infringing U.S. Patent Nos. 6924123 and 7056699.

Rights to the patents, both entitled Lentiviral LTR Deleted Vector, were exclusively licensed for research use to Sigma-Aldrich by Oxford BioMedica in October 2005, according to a news release.

The suit states that, among other products, Open Biosystems' Lentiviral shRNAmir library is marketed and sold to researchers and research institutions for incorporation into viral particles that infringe one or more claims of the patents.

Sigma-Aldrich is a life-sciences company based in Chicago.

Oxford BioMedica is a gene-therapy company with U.S. headquarters in San Diego.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.